贝达喹啉治疗耐药结核病的研究进展

Progress on Bedaquiline in Treating Drug-resistant Tuberculosis

耐药结核病是全球结核病控制规划面临的主要挑战,需要采用二线抗结核药物治疗,但治疗效果并不十分理想,故亟须研究和开发新型抗结核药物。贝达喹啉(bedaquiline)是过去40多年中美国食品药品监督管理局(FDA)批准用于治疗耐药结核病的第一种药物,该药能有效提高耐药结核病的临床疗效及缩短治疗时间。本文综述了贝达喹啉治疗耐药结核病的作用机制、临床试验、不良反应和药物-药物相互作用及耐药机制的研究进展,以提高临床对贝达喹啉的认识。

Drug-resistant tuberculosis is the major challenge in Global Tuberculosis Control Programme,which needs second-line anti-tuberculosis drugs,but the treatment outcome is not very ideal,so we should develop new anti-tuberculosis drugs. Bedaquiline was the first drug for drug-resistant tuberculosis that approved by FDA in the past 40 years,can effectively improve the clinical effect and shorten the curative time in treating drug-resistant tuberculosis. This paper reviewed the action mechanism,clinic trials,adverse reactions,drug-drug interaction and drug resistance mechanism of bedaquiline in treating drug-resistant tuberculosis,in order to improve the clinical acquaintance of bedaquiline.